1
40
3
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1185/030079904x2558" target="_blank" rel="noreferrer noopener">http://doi.org/10.1185/030079904x2558</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
1473-1481
Issue
9
Volume
20
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Clinical Implications Of 750mg, 5-day Levofloxacin For The Treatment Of Community Acquired Pneumonia
Publisher
An entity responsible for making the resource available
Current Medical Research and Opinion
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-09
Subject
The topic of the resource
adults; antimicrobial therapy; community-acquired pneumonia; controlled-trial; critical pathway; early switch; General & Internal Medicine; guidelines; levofloxacin; management; oral antibiotics; Research & Experimental Medicine; resolution; short-course; symptom
Creator
An entity primarily responsible for making the resource
File T M; Milkovich G; Tennenberg A M; Xiang J X; Khashab M M; Zadeikis N
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1185/030079904x2558" target="_blank" rel="noreferrer noopener">10.1185/030079904x2558</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article or Conference Abstract Publication
2004
adults
antimicrobial therapy
Community-acquired pneumonia
controlled-trial
critical pathway
Current medical research and opinion
early switch
File T M
General & Internal Medicine
guidelines
Khashab M M
Levofloxacin
Management
Milkovich G
oral antibiotics
Research & Experimental Medicine
resolution
short-course
symptom
Tennenberg A M
Xiang J X
Zadeikis N
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1185/030079904x3096" target="_blank" rel="noreferrer noopener">http://doi.org/10.1185/030079904x3096</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
1511-1521
Issue
10
Volume
20
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Managing patients with recurrent acute exacerbations of chronic bronchitis: a common clinical problem
Publisher
An entity responsible for making the resource available
Current Medical Research and Opinion
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-10
Subject
The topic of the resource
acute exacerbation; acute otitis media; airway inflammation; antimicrobial resistance; chronic bronchitis; chronic obstructive; community-acquired pneumonia; disease; empiric therapy; General & Internal Medicine; haemophilus-influenzae; moraxella-catarrhalis; obstructive-pulmonary-disease; pneumococcal; pneumonia; pulmonary; Research & Experimental Medicine; resistance; resistant streptococcus-pneumoniae; surveillance program
Creator
An entity primarily responsible for making the resource
Sethi S; File T M
Description
An account of the resource
Chronic obstructive pulmonary disease (COPD) affects 15 million people and is the fourth leading cause of death in the United States. It places a considerable burden on the healthcare system, with exacerbations contributing to a significant proportion of this burden. Patients with recurrent exacerbation, who experience more than 2 exacerbations per year, are especially difficult to manage. Several potential host, pathogen, and treatment factors can be identified that contribute to recurrent exacerbation. Patients with recurrent exacerbations are often exposed to frequent courses of antimicrobials. Therefore, antimicrobial resistance among common bacterial pathogens is likely to be prevalent in this group of patients, and further complicates therapy in this already difficult-to-treat patient population. In the management of patients with recurrent exacerbation, one goal should be to decrease the frequency of exacerbations, for which several strategies are suggested. In this article, we will review available literature identified through an extensive search of Medline and PubMed on the characteristics and approach to management of these difficult-to-treat patients. There is a substantial need for more research to understand the etiology and identify efficacious interventions to reduce the frequency of exacerbations of COPD.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1185/030079904x3096" target="_blank" rel="noreferrer noopener">10.1185/030079904x3096</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2004
acute exacerbation
acute otitis media
airway inflammation
Antimicrobial resistance
chronic bronchitis
chronic obstructive
Community-acquired pneumonia
Current medical research and opinion
Disease
empiric therapy
File T M
General & Internal Medicine
haemophilus-influenzae
Journal Article
moraxella-catarrhalis
obstructive-pulmonary-disease
pneumococcal
Pneumonia
pulmonary
Research & Experimental Medicine
resistance
resistant streptococcus-pneumoniae
Sethi S
surveillance program
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1185/030079904X2556" target="_blank" rel="noreferrer noopener">http://doi.org/10.1185/030079904X2556</a>
Pages
1473–1481
Issue
9
Volume
20
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Current medical research and opinion
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-09
Subject
The topic of the resource
*Levofloxacin; Administration; Adult; Anti-Bacterial Agents/*administration & dosage/economics; Bacterial/*drug therapy; Community-Acquired Infections/drug therapy; Drug Administration Schedule; Drug Costs; Female; Humans; Infusions; Intravenous; Male; Ofloxacin/*administration & dosage/economics; Oral; Pneumonia; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Milkovich Gary; Tennenberg Alan M; Xiang Jim X; Khashab Mohammed M; Zadeikis Neringa
Description
An account of the resource
OBJECTIVE: To evaluate the time to symptom resolution and i.v.-to-p.o. transition in community-acquired pneumonia (CAP) patients treated with 750 mg or 500 mg levofloxacin. RESEARCH DESIGN: A retrospective, subset analysis of a multicenter, randomized, double-blind, controlled trial comparing 750 mg levofloxacin for 5 days to 500 mg levofloxacin for 10 days for the treatment of CAP. PATIENTS AND METHODS: A total of 528 CAP patients were included. Baseline symptoms were re-evaluated on Day 3 of therapy, and time to i.v.-to-p.o. transition was recorded for inpatients. RESULTS: For the overall population, 67.4% of patients receiving 750 mg levofloxacin had resolution of fever by Day 3 of therapy, compared to 54.6% of 500 mg treated patients (P = 0.006). Patients who started on 750 mg levofloxacin i.v. (N = 108) transitioned to p.o. in an average of 2.68 days while those starting on 500 mg i.v. (N = 124) transitioned in 2.95 days (P = 0.144). The median time for i.v.-to-p.o. switch was 2.35 days and 2.75 days for patients receiving 750 mg and 500 mg levofloxacin, respectively (P = 0.098, log rank test). By Day 3 of therapy, 68% of patients receiving the 750 mg dose had transitioned from i.v. to p.o. levofloxacin, compared with 61% of the 500 mg group (P = 0.280). The safety profiles were comparable for the two regimens. CONCLUSIONS: The 750 mg levofloxacin dose resulted in a greater proportion of patients with resolution of CAP symptoms by Day 3 when compared with 500 mg therapy. Consequently, the 750 mg regimen trended toward more rapid transition to p.o., potentially resulting in lower overall drug costs. Time to switch from i.v. to p.o. was determined by the investigators' discretion rather than a set protocol. Additionally, length of stay data was not collected in this study, which can significantly impact overall healthcare costs. Further research is required to fully understand the economic impact of the 750 mg, 5-day levofloxacin regimen.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1185/030079904X2556" target="_blank" rel="noreferrer noopener">10.1185/030079904X2556</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Levofloxacin
2004
Administration
Adult
Anti-Bacterial Agents/*administration & dosage/economics
Bacterial/*drug therapy
Community-Acquired Infections/drug therapy
Current medical research and opinion
Department of Internal Medicine
Drug Administration Schedule
Drug Costs
Female
File Thomas M Jr
Humans
Infusions
Intravenous
Khashab Mohammed M
Male
Milkovich Gary
NEOMED College of Medicine
Ofloxacin/*administration & dosage/economics
Oral
Pneumonia
Tennenberg Alan M
Treatment Outcome
Xiang Jim X
Zadeikis Neringa